Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CLINICAL MEASUREMENT - ANNOTATIONS

The Clinical Measurement Ontology (CMO), Measurement Methods Ontology (MMO), and Experimental Condition Ontology (XCO) are currently being developed at the Rat Genome Database. For more information about these vocabularies please see Shimoyama et al. Three ontologies to define phenotype measurement data. Front Genet. 2012;3:87. Epub 2012 May 28 or contact us (http://rgd.mcw.edu/contact/index.shtml).

Term:prostate tumorous lesion incidence/prevalence measurement
go back to main search page
Accession:CMO:0000934 term browser browse the term
Definition:A measurement in which the number of individuals in a study population that display one or more prostate tumorous lesion(s) at a point in time or develop such lesions within a determined period of time are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio. A tumorous lesion is one which is or has the potential to become a tumor, that is, a neoplasm or new growth of tissue in which cell multiplication is more or less uncontrolled and progressive. Tumorous lesions include tumors, preneoplastic lesions, and hyperplastic lesions composed of histologically normal cells.



show annotations for term's descendants           Sort by:
percentage of study population developing ventral prostate tumorous lesions during a period of time term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Prcs1 Prostate cancer susceptibility QTL 1 IDA RGD PMID:15805257 RGD:1358944 NCBI chr19:15,114,598...34,521,833 JBrowse link
Q Prcs2 Prostate cancer susceptibility QTL 2 IDA RGD PMID:15805257 RGD:1358944 NCBI chr20:4,606,607...17,617,956 JBrowse link

Term paths to the root